Latest Intellia Therapeutics News & Updates

See the latest news and media coverage for Intellia. We track all announcements, press releases, and industry mentions in real time, all in one place.

Intellia Therapeutics (Intellia)

Clinical-stage genome editing company

intelliatx.com

Headquarters: Cambridge, United States
Founded year: 2014
Company type: Public company
Number of employees: 450–500

Last updated Today

Latest news about Intellia Therapeutics (Intellia)

In short: Intellia achieved positive Phase 3 results for its CRISPR gene-editing therapy and won a legal victory against investor misrepresentation claims.

Company announcements

June 13 Intellia

Intellia reports positive Phase 3 results for lonvo-z

Data showed 87% reduction in monthly attacks and favorable safety, with BLA submission initiated.

May 11 Intellia

Intellia announces Q1 2026 financial results and updates

Includes positive Phase 3 lonvo‑z data, a rolling BLA filing, resumed nex‑z Phase 3 screening, and approximately $207 million raised, supporting operations into 2028.

April 29 Intellia

Intellia Therapeutics announces pricing of public offering of common stock

The offering of 16.7 million shares at $10.75 per share is expected to raise approximately $180 million.

April 27 Intellia

Intellia announces proposed public offering of $150 million common stock

The offering includes an underwriters' option for additional shares, with Jefferies, Goldman Sachs, and Citigroup as joint book-runners.

Media coverage

Yesterday Genetic Engineering and Biotechnology News

StockWatch: Positive Phase III Data Sells Investors on Intellia

A second positive Phase III data readout in two months is a major reason why Intellia Therapeutics shares have soared more than 76% over the...

June 18 Bloomberg Law

Intellia Dispatches Suit Over Gene-Editing Therapy’s Prospects

Intellia Therapeutics Inc. investors can’t proceed with a proposed class action alleging the biotechnology company misrepresented the timeline and animal data for a gene-insertion therapy...

June 17 GuruFocus

Intellia Therapeutics (NTLA) Sees 10.7% Surge in Stock Price

On June 17, 2026, Intellia Therapeutics Inc NTLA experienced a noteworthy increase in its stock value, rising by 10.7%, which translates to a gain of...

June 15 Yahoo Finance

NTLA Posts Strong Additional Phase III Data From HAE Study, Stock Up

Intellia jumps after additional phase III HAELO data showed lonvo-z cut on-demand-treated attacks by 89% and moderate-to-severe episodes by 91%.

Never miss news about Intellia

Track Intellia and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Intellia competitors & trending companies

Browse news for competitors to Intellia and other trending companies.